Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis

Background: Ischemic stroke and myocardial infarction are fatal diseases and are among the top 10 causes of death in Korea, including arterial thromboembolic events. Many previous studies have described the function of interleukin-6 (IL-6) in arterial thromboembolic events and the association between promoter single-nucleotide polymorphism (SNP) (rs1800795; -174, G/C) of the IL-6 gene. However, these results were controversial. Therefore, we performed a meta-analysis to more precisely assess the association between the SNP of the IL-6 gene and susceptibility to arterial thromboembolic events.

Material/Methods: We used PubMed, Embase, Google Scholar, and Korean Studies Information Service System (KISS) electronic databases. Comprehensive Meta-analysis software (Corporation, NJ) was used to evaluate the relationship between rs1800795 SNP of IL-6 gene and risk of arterial thromboembolic events. Odds ratio (OR), 95% confidence interval (CI), and P value were also calculated. The 13 eligible studies were analyzed in the meta-analysis.

Results: The present meta-analysis found that rs1800795 SNP of IL-6 gene is not significantly associated with susceptibility to arterial thromboembolic events (C allele vs. G allele, OR=1.04, 95% CI=0.91–1.19, P=0.619; CC vs. CG+GG, OR=1.09, 95% CI=0.91–1.31, P=0.364; CC+CG vs. GG, OR=0.97, 95% CI=0.78–1.21, P=0.763, respectively), and the SNP of IL-6 gene also did not show any significant association with ischemic stroke or myocardial infarction (P>0.05 in each model).

Conclusions: We found that rs1800795 SNP of IL-6 gene was not related to arterial thromboembolic events. However, further study will be needed to confirm these results.

MeSH Keywords: Interleukin-6 • Meta-Analysis • Polymorphism, Genetic
**Background**

Arterial thromboembolic events may be caused by arterial thrombosis, which is the formation of a thrombus within an artery. Arterial thrombosis is closely related to arterial diseases such as ischemic stroke and myocardial infarction [1]. According to the American Heart Association, stroke is a fatal cerebrovascular disease and the leading cause of death and disability in the United States. In Korea, stroke is the second most common cause of death, and in 2014 it accounted for 50.3 deaths per 100 000 people aged over 65 years, according to Statistics Korea [2]. The age-standardized incidence of ischemic stroke in the population of people aged 35–74 years has been increasing annually, and ischemic stroke accounted for 76% of all cases of strokes in 2009, with a 90-day mortality rate of 3–7% [3]. Statistics Korea also reported 19.6 deaths due to myocardial infarction per 100 000 people in Korea in 2012 (http://kostat.go.kr).

Many pro-inflammatory cytokines are known to be involved in the risk of myocardial infarction and stroke. Cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) could play important roles in stroke and have been detected in the cerebrospinal fluid of patients with stroke [4]. Several studies have suggested that plasma levels of TNF-α and IL-6 are associated with patient prognosis following ischemic stroke [5]. Associations between IL-6 and atherosclerosis and cardiovascular disease have also been previously reported [6]. Additionally, previous epidemiological data have shown that IL-6 is associated with clinical and subclinical cardiovascular diseases [7]. IL-6 plays a major role in the synthesis of human acute-phase protein, and plasma IL-6 levels are elevated in patients with acute myocardial infarction [8]. A previous in vivo study found that IL-1β stimulates myocardial injury after IL-6 is induced in endothelial cells and fibroblasts [9]. IL-6 induces a prothrombotic state by increasing expression of tissue factor, activation of endothelial cells, and increasing platelet production, and by reducing the levels of inhibitors of hemostasis [10].

IL-6 gene is located at 7p21 and encodes a cytokine that plays a role in inflammation and B cell maturation (http://www.ncbi.nlm.nih.gov). Two single-nucleotide polymorphisms (SNPs), -174, G/C SNP and -572, G/C SNP have been identified in the promoter region of the IL-6 gene, which might have an effect on IL-6 transcription and plasma IL-6 levels [11–13]. The rs1800795 polymorphism has been examined in many previous studies. An association between *Helicobacter pylori* infection and decreased high-density lipoprotein (HDL) levels could be transmitted through its genotype of the IL-6 gene [14]. In patients with type 2 diabetes, rs1800795 SNP of the IL-6 gene is significantly related to increased risk of cardiovascular disease [15]. In addition, rs1800795 SNP of the IL-6 gene is related with autoimmune diseases such as systemic lupus erythematosus [16], systemic sclerosis [17], and autoimmune thyroid disease [18]. Although several previous studies have investigated the association between rs1800795 polymorphism and ischemic stroke or myocardial infarction risk, these results remain controversial. As the evidence suggests that IL-6 plays a major role in thromboembolic mechanisms, the aim of this meta-analysis was to evaluate the association between rs1800795 polymorphism (-174, G/C) of the IL-6 gene and arterial thromboembolic events.

**Material and Methods**

**Search strategy**

For the meta-analysis, we searched for published studies that considered the relationship between arterial thromboembolic events and polymorphism of the IL-6 gene. To identify all eligible studies that investigated the association between -176, G/C SNP of the IL-6 gene and susceptibility of arterial thromboembolic events, we performed a literature search in PubMed, Embase, Google Scholar, and Korean Studies Information Service System (KISS) electronic databases until January 1, 2016. The search terms were; “interleukin-6”, “IL-6”, or “IL6”, AND “polymorphism”, “polymorphisms”, or “variant” AND “rs1800795”, or“-174” AND “ischemic stroke”, “myocardial infarction”. We also searched previous meta-analyses of IL-6 gene polymorphism (-174, G/C polymorphism) and ischemic stroke or myocardial infarction.

**Inclusion criteria**

Studies were included if they met the following criteria: (1) evaluated the association between the IL-6 polymorphism (-174, G/C) and ischemic stroke or myocardial infarction; (2) study design using the methodology of a case-control study; (3) complete distribution of polymorphism (-174, G/C) of the IL-6 gene in the disease group and the control group to determine odds ratio (OR), 95% confidence interval (CI), and P value; (4) only studies in white populations were included, and studies of Asian populations were excluded.

**Data extraction**

Two investigators independently searched titles and abstracts in articles. Irrelevant and incompatible studies were excluded. The investigators extracted data and reached consensus on all of the items. If the investigators generated different results, they checked the data again and had a discussion to come to an agreement. The following information were extracted from each study: (1) first author’s name; (2) year of publication; (3) country; (4) number of cases and controls; (5) genotype frequency of IL-6 gene polymorphism (-174, C/G).
Table 1. Information of eligible studies included in the meta-analysis.

| Study                  | Country | Disease       | Case/control | Case G/C | Case G/G | Control G/C | Control G/G | Case G | Control G | HWE in Control |
|------------------------|---------|---------------|--------------|----------|----------|-------------|-------------|--------|-----------|----------------|
| Revilla et al. (2002)  | Spain   | IS            | 82/82        | 4/15     | 27/6     | 39/13       | 37/4        | 70/94  | 51/113    | 0.32           |
| Balding et al. (2004)  | Ireland | IS            | 105/389      | 12/6     | 33/6     | 198/123     | 84/126      | 334/444 | 4.45      |                |
| Flex et al. (2004)     | Italy   | IS            | 237/223      | 22/6     | 100/6    | 68/99       | 56/159      | 315/235 | 211/0.10  |                |
| Chamorro et al. (2005) | Spain   | IS            | 273/105      | 35/13    | 104/9    | 50/46       | 204/342     | 68/142  | 0.37      |                |
| Lalouschek et al. (2006)| Austria | IS            | 404/415      | 74/187   | 143/67   | 192/156     | 335/473     | 326/504 | 0.54      |                |
| Bazina et al. (2015)   | Croatia | IS            | 114/187      | 22/53    | 39/26    | 98/63       | 97/131      | 150/224 | 0.21      |                |
| Georges et al. (2001)  | France  | MI            | 614/672      | 104/340  | 170/105  | 336/231     | 548/680     | 546/798 | 0.35      |                |
| Nauck et al. (2002)    | Germany | MI            | 2575/729     | 261/668  | 436/144  | 355/230     | 1190/1540   | 643/815 | 0.74      |                |
| Licastro et al. (2004) | Italy   | MI            | 138/97       | 15/88    | 35/7     | 44/46       | 118/158     | 58/136  | 0.42      |                |
| Lieb et al. (2004)     | Germany | MI            | 1322/1023    | 244/627  | 451/193  | 499/331     | 1115/1529   | 885/1161 | 0.84      |                |
| Kelberman et al. (2004)| UK      | MI            | 507/561      | 61/219   | 227/81   | 240/240     | 347/673     | 402/720 | 0.10      |                |
| Chiappelli et al. (2005)| Italy  | MI            | 138/204      | 21/112   | 71/24    | 106/127     | 154/254     | 154/360 | 0.78      |                |
| Bennermo et al. (2011) | Sweden  | MI            | 356/378      | 87/150   | 119/93   | 176/109     | 324/388     | 362/394 | 0.19      |                |

IS – ischemic stroke; MI – myocardial infarction; HWE – Hardy-Weinberg equilibrium.

Statistical analysis

Comprehensive meta-analysis software (Corporation, NJ) was used to perform the meta-analysis. The pooled OR, 95% CI, and P value were used to measure associations between susceptibility of arterial thromboembolic events and IL-6 polymorphism (-174, G/C). Firstly, we calculated the heterogeneity of studies. Heterogeneity among studies was assessed using the Q statistic and I² test. When the result of the Q test was P<0.05 or I² statistic was >50%, the random-effects Mantel-Haenszel method was used to determine if there was significant heterogeneity between studies. When the result of the Q test was P>0.05 or I² statistic was <50%, the fixed-effects Mantel-Haenszel method was used.

For meta-analysis of IL-6 gene polymorphism (-174, C/G), the pooled ORs, 95% CI, and p value were calculated using combination of genotype. We first estimated the risks of “C allele vs. G allele”, “C/C genotype+C/G genotype vs. G/G genotype”, and “C/G genotype vs. C/G genotype+G/G genotype” on arterial thromboembolic events, assuming dominant and recessive effects of the variant C allele, respectively. Subgroup analyses were carried out by ischemic stroke or myocardial infarction. The P<0.05 was regarded as a statistically significant association.

Results

Study characteristics

To assess the association between polymorphism (-174, G/C) of IL-6 gene and susceptibility to arterial thromboembolic events, related studies were retrieved based on the search strategy. First, we searched related studies on arterial thromboembolic events including ischemic stroke and myocardial infarction. Our meta-analysis was limited to case-control design with promoter polymorphism (-174, G/C) of the IL-6 gene and ischemic stroke or myocardial infarction in white populations. Although 6 articles were studied with polymorphism (-174, G/C) of IL-6 gene and susceptibility of ischemic stroke or myocardial infarction in Asian populations [19–24], the articles were excluded in the meta-analysis. Finally, 13 eligible articles were selected [25–37]. The characteristics of these 13 eligible studies are summarized in Table 1. The 13 studies consisted of 6 articles on ischemic stroke and 7 articles on myocardial infarction.

Quantitative synthesis for arterial thromboembolic events

Table 2 and Figure 1 shows overall results between IL-6 gene polymorphism (-174, G/C) and susceptibility to arterial thromboembolic events. We analyzed whether risk of the C allele and combined genotype of the SNP were related with susceptibility of arterial thromboembolic events. The results of the Q test were P value or I² statistic in analysis of C allele vs. G allele, CC
Publication bias was calculated. The funnel plot was symmetrical (data not shown), suggesting that there was no publication bias. Additionally, Egger’s test showed quantitative evidence for absence of publication bias (P>0.05 in each model, Table 2).

To assess publication bias, Begg’s funnel plot was used out and Egger’s test was calculated. The funnel plot was symmetrical (data not shown), suggesting that there was no publication bias. Additionally, Egger’s test showed quantitative evidence for absence of publication bias (P>0.05 in each model, Table 2).

Table 2. Overall analysis between interleukin-6 polymorphism (-174, G/C) and susceptibility of arterial thromboembolic events.

| Comparison | Heterogeneity | Model | Association test OR (95% CI) | P | Egger’s test P |
|------------|---------------|-------|-----------------------------|---|---------------|
| IS+MI      | C vs. G       | <0.001| 80.941                      | Random 1.04 (0.91–1.19) | 0.619 | 0.454 |
| IS         | C vs. G       | <0.001| 87.738                      | Random 0.99 (0.70–1.40) | 0.930 | 0.642 |
| MI         | C vs. G       | 0.002 | 70.814                      | Random 1.07 (0.94–1.22) | 0.319 | 0.090 |
| IS+MI      | CC vs. CG+GG  | <0.001| 75.820                      | Random 1.09 (0.91–1.31) | 0.364 | 0.321 |
| IS         | CC vs. CG+GG  | 0.002 | 72.982                      | Random 0.99 (0.70–1.39) | 0.929 | 0.734 |
| MI         | CC vs. CG+GG  | <0.001| 80.143                      | Random 1.17 (0.93–1.46) | 0.187 | 0.080 |
| IS+MI      | CC+CG vs. GG  | <0.001| 71.398                      | Random 0.97 (0.78–1.21) | 0.763 | 0.783 |
| IS         | CC+CG vs. GG  | <0.001| 86.953                      | Random 0.98 (0.50–1.92) | 0.931 | 0.706 |
| MI         | CC+CG vs. GG  | 0.827 | <0.001                     | Fixed 0.99 (0.88–1.11)  | 0.778 | 0.290 |

We also performed subgroup analyses of ischomic stroke and myocardial infarction. However, IL-6 gene polymorphism (-174, G/C) did not show any significant association with ischemic stroke (C allele vs. G allele, OR=0.99, 95% CI=0.94–1.40, P=0.930; CC genotype vs. CG genotype+GG genotype, OR=0.99, 95% CI=0.70–1.39, P=0.929; CC genotype+CG genotype vs. GG genotype, OR=0.98, 95% CI=0.50–1.92, P=0.931, respectively) (Table 2, Figure 2). In myocardial infarction (C allele vs. G allele, OR=1.07, 95% CI=0.94–1.22, P=0.319; CC genotype vs. CG genotype+GG genotype, OR=1.17, 95% CI=0.93–1.46, P=0.187; CC genotype+CG genotype vs. GG genotype, OR=0.99, 95% CI=0.88–1.11, P=0.778, respectively) (Table 2, Figure 3).

To assess publication bias, Begg’s funnel plot was used out and Egger’s test was calculated. The funnel plot was symmetrical (data not shown), suggesting that there was no publication bias. Additionally, Egger’s test showed quantitative evidence for absence of publication bias (P>0.05 in each model, Table 2).

**Discussion**

According to Statistics Korea, stroke and cardiovascular diseases were among the top 10 causes of death in Korea in 2014. Among them, stroke is the number 2 cause of death (http://kostat.go.kr). According to the Korea National Emergency Medical Center in 2014, a total of 26 208 patients visited emergency departments due to myocardial infarction and 430 patients died. A total of 91 924 stroke patients visited emergency departments due to stroke and 451 patients died in 2013 (http://www.nemc.or.kr). These diseases cause death and disability, creating burdens for patients, their families, society, and the world [3].

Therefore, there have been many attempts to predict or prevent these diseases. C-reactive protein (CRP) and creatinine in serum are used to predict coronary heart disease risk [38]. Red blood cell distribution width and calcium score can be used to assess cardiovascular event risk stratification and prevention [39]. Some authors developed risk scoring system for prediction of atypical symptom presentation in acute myocardial infarction patients [40]. Increase in the systemic inflammatory marker procalcitonin is related to no-reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction patients [41]. Hemorheological abnormalities, poor glycemic control, and low HDL cholesterol are used as markers and predictors for major adverse cardiovascular events and coronary heart disease in outpatients [42]. The ankle-brachial index is useful in predicting acute ischemic stroke [43].

Recently, many studies have reported the genetic contribution to predict or prevent these diseases. Several studies showed the genetic contribution to inflammatory and hemostatic
The odds ratio and 95% CI for CYP2C19 gene polymorphisms are associated with long-term recurrent risk of ischemic stroke [45]. Peroxisome proliferator-activated receptors could be a protective factor for ischemic stroke in the Chinese Han population [46]. A previous study showed that genetic factors are associated with age at stroke onset and sex [47]. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction.
risk [48]. Recently, there was an attempt to find predictors of myocardial infarction using genotype/allelic combinations by analysis of genotype frequencies of polymorphic markers [49].

Inflammatory cytokines in arterial lesions play various roles, including plaque formation and progression and vessel thrombosis [50]. Cytokines produce adhesion molecules, matrix metalloproteinases, and reactive oxygen species and induce the expression of the messenger cytokine IL-6, which causes the release of C-reactive protein, fibrinogen, and plasminogen activator inhibitor-1. These lead to atherothrombosis, which is the proximate cause of arterial thrombosis [51]. The genotype of IL-6 is also involved in this process. The IL-6 genotype was significantly associated with thrombosis in children [52] and increased risk of ischemic stroke [53].

Therefore, we performed this meta-analysis to examine the possible association between IL-6 rs1800795 polymorphism and ischemic stroke and myocardial infarction risks. However, we found no statistically significant association between the IL-6 rs1800795 polymorphism and ischemic stroke or myocardial infarction risks in any models.

In the present study, we collected previous studies on ischemic stroke or myocardial infarction and IL-6 polymorphism and could not find any associations. Our results agree with a
previous meta-analysis in 2012, which reported a significant association between IL-6 gene -174 G/C polymorphism and myocardial infarction risk in Asians but not in whites [54]. As there were few studies on Asians, we included only studies on whites and found no association. A previous study showed that pro-inflammatory and prothrombotic polymorphisms, including IL-6, were not associated with perinatal arterial ischemic stroke [55].

Conclusions

It is clear that IL-6 plays an important role in the initiation of thrombosis, resulting in ischemic stroke or myocardial infarction. However, we could not show any statistical significance in the models. It appears that IL-6 rs1800795 is not associated with ischemic stroke or myocardial infarction risk. Further studies including clinical features are needed to clarify the possible relationship between IL-6 rs1800795 polymorphism and the development of ischemic stroke or myocardial infarction.

Conflict of interest

None.
References:

1. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med, 2008; 359: 938–49
2. Sero SR, Kim SY, Lee SY et al: The incidence of stroke by socioeconomic status, age, sex, and stroke subtype: a nationwide study in Korea. J Prev Med Public Health, 2014; 47: 104–12
3. Hong KS, Bang OY, Kang DW et al: Stroke statistics in Korea: Part I. Epidemiology and risk factors: A report from the korean stroke society and clinical research center for stroke. J Stroke, 2013; 15: 2–20
4. Ferrarese C, Mascarucci P, Zoia C et al: Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab, 1999; 19: 1004–9
5. Tuttolomondo A, Di Raimondo D, di Sciacca R et al: Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des, 2008; 14: 3574–89
6. Suzuki S, Tanaka K, Suziki N: Ambivalent aspects of interleukin-6 in cerebral ischemia: Inflammatory versus neurotrophic aspects. J Cereb Blood Flow Metab, 2009; 29: 464–79
7. Cesar M, Penninx BW, Newman AB et al: Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC Study]). Am J Cardiol, 2003; 92: 522–28
8. Miyao Y, Yasue H, Ogawa H et al: Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J, 1993; 126: 1299–304
9. Guillet I, Blanes M, Gomez-Lechon MJ et al: Cytokine signaling during myocardial infarction: Sequential appearance of IL-1 beta and IL-6. Am J Physiol, 1995; 269: R229–35
10. Kerr R, Stirling D, Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol, 1982; 52: 427–32
11. Olomolaiye O, Wood NA, Bidwell JL: A novel NlaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet, 1998; 25: 1–7
12. Fishman D, Faulds G, Jeffery R et al: The effect of novel polymorphisms in the interleukin-2 gene on IL-2 transcription and plasma IL-2 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 1998; 102: 1369–76
13. Revilla M, Obach V, Poirier O et al: Interleukin-6 gene polymorphisms and myocardial infarction in Turkish population. Int J Cardiol, 2011; 157: 299–305
14. Bennermo M, Nordin M, Lundman P et al: Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: A case-control study. J Interferon Cytokine Res, 2011; 31: 259–64
15. Park S, Youn JC, Shin DJ et al: Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction. Coron Artery Dis, 2007; 18: 417–22
16. Kelbermann D, Hause E, Luang LA et al: Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost, 2004; 92: 1122–28
17. Salim A, Tai ES, Tan VY et al: The interleukin-1b promoter polymorphism in patients with acute myocardial infarction: A case-control study. J Interferon Cytokine Res, 2011; 31: 259–64
18. Oleksiak A, Kruk M, Lenarczyk E et al: Biomarkers for risk stratification in ACS: A role of red blood cell distribution width and calcium score. Atherosclerosis, 2015; 246: 57–62
19. Li PW, Yu DS: Recognition of atypical symptoms of acute myocardial infarction: Development and validation of a risk scoring system. J Cardiovasc Nurs, 2015 [Epub ahead of print]
20. Murat SN, Kurtal A, Celik IE et al: The association of serum procalcitonin level with the no-reflow phenomenon after a primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Coron Artery Dis, 2016; 27: 116–21
21. Cho SW, Kim BG, Kim BD et al: Hemorheological and glycemic parameters and HDL cholesterol for the prediction of cardiovascular events. Anq Bras Cardiol, 2016; 106: 56–61
22. Hao Z, Yang C, Tao W et al: Prognostic implications of the Ankle-Brachial Index in patients with acute ischemic stroke: A meta-analysis. Expert Rev Neurother, 2016; 16(3): 351–58
23. Williams SR, Hsu FC, Keene KL et al: Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke. Neurology, 2016; 86: 351–59
24. Yang L, Zhao Y, Wang N et al: Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2013; 32: 871–76 [In Chinese]
46. Tong Y, Cai L, Han S et al: Functional genetic variants of PPARβ/δ and PPARα encoding peroxisome proliferator-activated receptors and susceptibility to ischemic stroke in Chinese Han population. Cerebrovasc Dis, 2016; 41: 96–99

47. Traylor M, Rutten-Jacobs LC, Holliday EG et al: Differences in common genetic predisposition to ischemic stroke by age and sex. Stroke, 2015; 46: 3042–47

48. Guarrera S, Fiorito G, Onland-Moret NC et al: Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. Clin Epigenetics, 2015; 7: 133

49. Nasibullin TR, Timasheva YR, Sadikova RI et al: Genotype/allelic combinations as potential predictors of myocardial infarction. Mol Biol Rep, 2016; 43: 11–16

50. Shanker J, Kakkar VV: Implications of genetic polymorphisms in inflammation-induced atherosclerosis. Open Cardiovasc Med J, 2010; 4: 30–37

51. Packard RR, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem, 2008; 54: 24–38

52. Unal S, Gurnuk F, Aytac S et al: Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) levels and IL-6, TNF-polymorphisms in children with thrombosis. J Pediatr Hematol Oncol, 2008; 30: 26–31

53. Qi XF, Feng TJ, Yang P et al: Role of inflammatory parameters in the susceptibility of cerebral thrombosis. Genet Mol Res, 2014; 13: 6350–55

54. Yin YW, Hu AM, Sun QQ et al: Association between interleukin-6 gene -174 G/C polymorphism and the risk of coronary heart disease: A meta-analysis of 20 studies including 9619 cases and 10,919 controls. Gene, 2012; 503: 25–30

55. Gelfand AA, Croen LA, Torres AR et al: Genetic risk factors for perinatal arterial ischemic stroke. Pediatr Neurol, 2013; 48: 36–41